Interview With Michelle Janikian, Author, Host & Editor at Psychedelics Today

Project Angie: Can MindMed Disrupt the Pain Relief Industry? [MMED / MNMD Expanding Horizons]
Breaking NEWS: MindMed ( MNMD / MMED / MMQ ) launching a new flagship program called Angie to advance the development of psychedelics, including LSD and potentially penetrate the pain killer industry by treating pain conditions. MindMed is currently exploring two primary clinical indications for the treatment of pain:

MindMed will initiate a study of LSD in a severe pain indication. MMED is currently preparing a pre-IND briefing package for this Phase 2a Proof of Concept study. They plan to submit to the FDA in the second half of 2021.
( As a note, that means they could present this doc anywhere between July 1st and December 31st. So it is conceivable that this trial could start at the tail end of 2021, if this doc gets presented at the beginning of that period.)
The second indication that MindMed is evaluating is “the common, often debilitating, chronic pain syndrome”.

Link to the 1964 study testing the LSDs ability to treat pain in cancer patients, and it had dual surprising results

: file:///C:/Users/maria/Downloads/Study_of_Lysergic_Acid_Diethylamide_as_an.13.pdf
Link to the 2020 a study was published that had among its authors 2 prominent MindMed collaborators: Mattias Liechti and Kim Kuypers: https://journals.sagepub.com/doi/full…​
Link to the 2017study: https://www.ncbi.nlm.nih.gov/pmc/arti…​

Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/​
Link to MindMed ‘ s Press Release on Project Angie : https://mindmed.co/news/press-release…​

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa…​
https://benzinga.grsm.io/thepsychedel…​

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed​ #MindMedStock​ #MNMD

Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).

In this video, we’ll cover:
1. Compass Pathways’ Financials
2. Their IP
3. Therapists Training
4. Future Projects
5. Digital Technology

I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#CompassPathways #CMPS #MindMed

MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock

Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/

All Psychedelic Stock investors should take the time to listen to the conference calls of the companies they are investing in. That is doubly important for year-end calls, as often information is divulged on the direction of the company. If you are invested in MNMD or MMED stock, you need to listen to this call.

Follow us on Twitter:
The Psychedelic Investor: @psycInvestor
James: @Psy_Invest
Maria: @psy_holy
Psychedelic Spotlight: @PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Meet Kevin O’Leary, Rober Barrow, Daniel Carcillo and other psychedelic leaders @ the Benzinga Psychedelics Capital Conference.on April 19 @ Fontainebleau Hotel, Miami!
https://www.eventbrite.com/e/benzinga-psychedelics-capital-conference-spring-2022-tickets-238697028237?discount=PSYCHSPOTLIGHT15&fbclid=IwAR3tJFhoVfVWZvAyQuWSLEo3kJSmaq8VGnQQPz04NMhG3g7rHtSmRSAUq64

COUPON CODE: PSYCHSPOTLIGHT15

Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC

In this MindMed 2021 conference and earnings call, we gained important insights into the company’s many projects. These include: Project Lucy, which attempts to treat Anxiety using LSD; Project Angie, attempting to treat pain with LSD; Project Layla, attempting to treat addiction with 18-MC, and much more.

The company gives some updates on the science of psychedelics, as well as their hiring strategy and financial updates. MindMed is a company working on treating mental health conditions with psychedelics. They are a leading player in the shroom boom, and they aim to commercialize psychedelics as medicines.

Some of the questions MindMed is trying to answer are:

Can Psychedelics treat Mental Health conditions?

Can Psychedelics treat depression?

Can Psychedelics treat anxiety?

Can Psychedelics treat ADHD?

Can Psychedelics help with Autism?

Can Psychedelics help treat pain?

#MindMed #MNMD #MindMedStocks